Alexion Pharmaceuticals (ALXN +4.2%) moves up on talk that Roche (RHHBY.PK +1.2%) is considering...

|About: Alexion Pharmaceuticals, Inc. (ALXN)|By:, SA News Editor

Alexion Pharmaceuticals (ALXN +4.2%) moves up on talk that Roche (RHHBY.PK +1.2%) is considering a bid as high as $128 for the company. That might be an expensive price tag for a "one trick pony," however, considering company has only one commercially approved drug, Solaris, whose distincion is that it's considered the most expensive drug on the market - with an average cost of over $400k per patient.